NCT04456322View on ClinicalTrials.gov

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

May 11, 2024

Study Completion Date

May 11, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

RT plus Nimotuzumab

Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)

DRUG

RT plus Cisplatin

concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )

Trial Locations (1)

510060

Sun Yat-sen Universitty Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04456322 - Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter